elbion AG clinical trials

Acquired by Acorda Therapeutics, Apr 11, 2016 · source ↗

The registry lists 2 studies whose lead sponsor is elbion AG. 0 are recruiting or about to start. Per ClinicalTrials.gov, last updated Aug 8, 2007.

Before and after it joined Acorda Therapeutics

First submitted before elbion AG became part of Acorda Therapeutics: 2
First submitted after elbion AG became part of Acorda Therapeutics: 0
Unclear, or no submission date: 0

By the date each study was first submitted to the registry. The registry lists today's sponsor name and keeps no history, so this says when a study was filed, not who filed it.

Status

Terminated: 2

Phase

Phase 2: 2

Where

Germany: 2
Sweden: 1
Poland: 1
Netherlands: 1

Registry sponsor names on this page

elbion AG2 studies

Something wrong with this grouping? Tell us on the Acorda Therapeutics page.

Studies

Recruiting first, then most recently updated. Showing 2 of 2. All Acorda Therapeutics studies →

ELB245 for 12 Weeks Versus 4mg Tolterodine in Patients With Incontinent Overactive Bladder (OAB)TerminatedNCT00439192Phase 2
Sponsor listed in the registry: elbion AG · First submitted before elbion AG became part of Acorda Therapeutics
ELB139 Given Orally to Patients With Concurrent Panic Disorder, Challenged by CO2 Inhalation After a Single Dose and One Week of TreatmentTerminatedNCT00322803Phase 2
Sponsor listed in the registry: elbion AG · First submitted before elbion AG became part of Acorda Therapeutics